Ascelia Pharma AB (CHIX:ACES) Research & Development: kr55.31 Mil (TTM As of Mar. 2026)


CHIX:ACES Ascelia Pharma AB CHIX:ACES
37 GF Score
Price kr3.29
! 1 Warning Sign
View Full Analysis

What is Ascelia Pharma AB Research & Development?

Ascelia Pharma AB CHIX:ACES 37 Research & Development is kr55.31 Mil as of Mar. 2026. GuruFocus rates CHIX:ACES with a GF Score™ of 37/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Ascelia Pharma AB's Research & Development for the three months ended in Mar. 2026 was kr14.16 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was kr55.31 Mil.

Ascelia Pharma AB  (CHIX:ACEs) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Ascelia Pharma AB Research & Development Related Terms

Ascelia Pharma AB Research & Development Historical Data

* Premium members only.

The historical data trend for Ascelia Pharma AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascelia Pharma AB Research & Development Chart

Ascelia Pharma AB Annual Data
Trend Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only 107.57 118.11 81.27 50.80 56.82

Ascelia Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.66 18.66 10.89 11.61 14.16
CHIX:ACES
37GF Score
Ascelia Pharma AB CHIX:ACES
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascelia Pharma AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr55.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of kr55.31 Mil mean?
Ascelia Pharma AB (CHIX:ACES) has a Research & Development of kr55.31 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Ascelia Pharma AB and its competitors.
Is Ascelia Pharma AB's Research & Development too high?
Ascelia Pharma AB's current Research & Development is kr55.31 Mil. Overall, Ascelia Pharma AB has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Ascelia Pharma AB's Research & Development compare to VRTX and REGN?
Ascelia Pharma AB's Research & Development of kr55.31 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Ascelia Pharma AB and its competitors. Ascelia Pharma AB's current Research & Development is kr55.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascelia Pharma AB stock overvalued right now?
Ascelia Pharma AB (CHIX:ACES) has a current Research & Development of kr55.31 Mil. The current Research & Development is kr55.31 Mil. Ascelia Pharma AB's overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Ascelia Pharma AB (CHIX:ACES), the current Research & Development is kr55.31 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascelia Pharma AB Business Description

Other Exchanges ACE:Sweden
Address Hyllie Boulevard 34, Malmo, SWE, 215 32
Ascelia Pharma AB is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. It has two drug candidates, Orviglance and Oncoral, in development. Orviglance (manganese chloride tetrahydrate) is an oral contrast agent for MR imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with impaired kidney function, and Oncoral is a novel oral irinotecan tablet in development.
37GF Score

Get the complete analysis for CHIX:ACES

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr3.29
Price